Phase 1 Brain Cancer Trial, Recruiting NCT05565118 Sponsor: Case Comprehensive Cancer Center Condition: Brain Cancer
Back to Brain Cancer

Phase 1 Brain Cancer Trial, Recruiting

NCT05565118
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have brain scan (MRI) findings that appear to show a high-grade glioma (a fast-growing type of brain tumour, WHO Grade 3 or 4, including a type called GBM), or people who have already been diagnosed with this type of brain tumour and are having surgery to remove a tumour that has come back or grown
  • People aged 18 or older
  • People who have had a detailed brain MRI scan within the month before surgery
  • People with a general health and functioning score of 60 or higher on a standard medical scale called the Karnofsky Performance Status (this roughly means able to care for most personal needs with occasional assistance — confirm with trial site)
  • People who are willing and able to sign a written consent form (or have a legal representative do so on their behalf)
  • People whose recent blood test results (taken within one month before surgery) meet the following requirements:
    • A type of white blood cell count (neutrophils) of at least 1,500 per microlitre
    • Platelet count of at least 100,000 per microlitre
    • Blood clotting test results within an acceptable range (or within the intended treatment range if already taking blood thinners)
    • A negative pregnancy test from urine or blood (not required for people who have had both ovaries and/or the uterus removed, or who are post-menopausal)

Who may not be able to join:

  • People with serious other health conditions that the treating doctor believes would make surgery too risky
  • People with other major physical illnesses or mental health conditions that the investigator believes would prevent safe completion of the trial treatment
  • People who are currently pregnant
  • People who have blood clotting problems or platelet disorders that raise the risk of bleeding during or after surgery
  • People whose tumour is located in a sensitive or critical area of the brain — such as areas that control movement, sensation, speech, vision, balance, or basic body functions — where the surgical procedure used in this trial cannot safely be performed, as determined by the neurosurgeon

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Jennifer Yu, MD, PhD, Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center

Phone: 1-866-223-8100

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
9 April 2024
Est. completion
1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Correlation between electrical activity and anatomic region of progression based on follow-up contrast-enhanced MRI

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov